Navigation Links
Cytochroma appoints Steven I. Engel as Vice President of Regulatory Affairs and Quality Assurance
Date:9/16/2008

MARKHAM, ON, Sept. 16 /PRNewswire/ - Cytochroma today announced that it has appointed Steven I. Engel, M.S., Pharm.D., as Vice President, Regulatory Affairs and Quality Assurance. Dr. Engel brings to Cytochroma over 20 years of experience in regulatory affairs and quality assurance, and will be responsible for directing all of Cytochroma's regulatory activities, as well as ensuring that the Company has appropriate quality systems in place. He will be based in Cytochroma's Illinois office.

"Cytochroma's activities in the areas of clinical and regulatory affairs are increasing significantly as we advance three lead product candidates through clinical development," stated Charles W. Bishop, Ph.D., Cytochroma's President and CEO. "For this reason, we have named Dr. Joel Melnick as Vice President, Clinical Research and Development and assigned his former responsibilities in the areas of regulatory affairs and quality assurance to Dr. Steve Engel. Steve has a proven track record of successful new drug registrations and post-marketing support, and we are pleased to have an individual of this caliber helping us secure global regulatory approvals for our products."

Prior to joining Cytochroma, Dr. Engel was Vice President of Regulatory Affairs and Clinical Quality Compliance at Par Pharmaceutical, Inc. where he was responsible for the regulatory strategies of both branded and generic pharmaceutical programs. Prior to joining Par Pharmaceutical, Dr. Engel held regulatory positions at AlgoRx Pharmaceuticals, Vertex Pharmaceuticals, Baxter Healthcare, Abbott Laboratories, Otsuka America Pharmaceuticals, G.D. Searle, and American Cyanamid. He earned his Doctor of Pharmacy degree from the University of Florida, his Master of Science in Pharmacology from the University of North Carolina at Chapel Hill, and his Bachelor's degrees in Pharmacy and Biology from Drake University.

"Cytochroma's portfolio of therapies for chronic kidney disease has tremendous
'/>"/>

SOURCE Cytochroma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cytochroma and Mitsubishi Tanabe form partnership for chronic kidney disease therapies in U.S. and Asia
2. Cytochroma Closes $45 Million Series C Financing
3. Cytochroma Appoints R. Richard Wieland II As CFO
4. Cytochroma opens U.S. headquarters in Illinois
5. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
6. Exosome Diagnostics Appoints Johan Skog, Ph.D., as Director of Genetics Research
7. Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors
8. China Yingxia International, Inc. Appoints New Vice President of Finance
9. SoluBest Appoints Michael Sheckler, MBA, as CEO
10. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
11. Affitech Appoints Dr. Keith McCullagh as Chairman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... 30, 2015    Intrexon Corporation (NYSE: ... and Merck Serono, the biopharmaceutical business of Merck ... announced an exclusive strategic collaboration and license agreement ... (CAR-T) cancer therapies. This collaboration advances Merck Serono,s ... modulate the immune system,s natural ability to fight ...
(Date:3/30/2015)... , March 30, 2015 ... biological drugs to treat cancer, viral infections and ... Sir John Bell , the Regius Professor ... the Office for the Strategic Coordination of Health ... effect.      (Photo: http://photos.prnewswire.com/prnh/20150330/736483 ...
(Date:3/30/2015)... TOKYO and MADISON, Wis. ... Shigehiro Nakajima ,) (TSE: 4901) ("Fujifilm") and Cellular ... (NASDAQ: ICEL ) ("CDI"), a leading developer and ... to precise specifications, today announced that the two companies ... acquire CDI via an all-cash tender offer to be ...
(Date:3/29/2015)... 29, 2015 Caris Life Sciences® ... data showing the presence of PD-1 and ... samples. Using Caris Molecular Intelligence®, the company,s ... expression of programmed cell death protein-1 (PD-1) ... while its ligand (PD-L1) expression was variable ...
Breaking Biology Technology:Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Immunocore Appoints Professor Sir John Bell to its Board of Directors 2Immunocore Appoints Professor Sir John Bell to its Board of Directors 3Immunocore Appoints Professor Sir John Bell to its Board of Directors 4Immunocore Appoints Professor Sir John Bell to its Board of Directors 5Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 2Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 3Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 4Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 5Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 6Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 7Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 8Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 2Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 4
... ... use in the 2009 Corporate Sustainability Report. , ... Madison, WI USA (PRWEB) June 22, 2010 -- Promega ... . This report summarizes Promega goals and accomplishments to conserve natural resources, minimize environmental ...
... have developed a simple new method for producing large ... works at room temperature, needs little processing, and paves ... An atom-thick sheet of carbon arranged in a ... and is considered a potential heir to copper and ...
... June 21 A global research team led by ... a new study in the Proceedings of the National Academy ... louse genome. Lead author, Ewen Kirkness , Ph.D., JCVI, ... analysis of the genome was then conducted by a large ...
Cached Biology Technology:Promega Releases 2009 Corporate Sustainability Report 2Researchers at Rensselaer Polytechnic Institute develop new method for mass-producing graphene 2Researchers at Rensselaer Polytechnic Institute develop new method for mass-producing graphene 3Multinational Research Team Led by J. Craig Venter Institute's Ewen Kirkness Sequence Body Louse Genome 2Multinational Research Team Led by J. Craig Venter Institute's Ewen Kirkness Sequence Body Louse Genome 3
(Date:3/10/2015)... BOULDER, Colo. , March 10, 2015 ... Space Flight "Personalized Medicine in Human ... Ph.D. and Thomas J. Goodwin , Ph.D. was ... articles of the past two years. Specifically, ... three most downloaded scientific papers published in 2013 and ...
(Date:3/10/2015)... OXFORD, Conn. , March 10, 2015 /PRNewswire/ ... NXTDW) ("NXT-ID" or the "Company"), a biometric authentication ... reports the company,s Wocket™ smart wallet has been ... 2015" by Rethink Modern. Rethink Modern ... sharing modern and innovative items for your home and lifestyle that ...
(Date:3/4/2015)... , Mar. 04, 2015 Research and Markets ... addition of the "Global Biometrics Market Forecast ... The market for biometric authentication systems ... around 14% till 2020 The driving ... increasing security needs, government projects and constant development ...
Breaking Biology News(10 mins):"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3
... for genetic diseases during in vitro fertilization offers couples ... genetic glitch could potentially cause doctors to misdiagnose a ... , Citing concerns about the accuracy of preimplantation ... the healthiest embryos during IVF, UF researchers set out ...
... a bid to facilitate collaboration among other biomolecular ... Laboratory has become the first institution outside the ... Consortium of Great Britain. , The BioSimGrid was ... Oxford, Southampton, Bristol, Birkbeck, Nottingham and York. Researchers ...
... lead is a well-known human health hazard, researchers at the ... of how it may work in mice to harm the ... bacteria, viruses and other bugs. , The discovery adds insight ... their emphasis from the immediate public health threat to understanding ...
Cached Biology News:Genetic testing still smart choice, despite uncertainties 2Genetic testing still smart choice, despite uncertainties 3Grid bridges 4,800 miles for molecular repositories 2The dangerous legacy of lead 2
... ATPase α-1, clone C464.6 GenBank Accession ... Na + /K + ATPase isolated ... medulla Formulation: 0.1M Tris-glycine, pH 7.4, 0.15M ... routinely evaluated in immunoblot on rat brain ...
Immunogen: Purified native p24 from strain IIIB. Storage: -20 C, Avoid Freeze/Thaw Cycles...
EDG-1CT (endothelial cell differentiation gene-1, C terminal)...
Request Info...
Biology Products: